VANCOUVER, Dec. 14, 2018 /CNW/ - Harvest One Cannabis Inc. (TSXV: HVT) ("Harvest One" or the "Company") today announced that the Board of Directors (the "Board") has named Mr. Frank Holler as Chairman effective immediately. Mr. Holler first joined the Board as a Director in September 2018. Peter Wall, Harvest One's former Chairman of the Board, will remain on the Board as a Director.
Grant Froese, Harvest One's CEO commented, "Frank's experience, particularly in the pharmaceutical industry and capital markets, strengthens the depth of expertise on the Harvest One Board. We're delighted he's stepping in as Chairman as this further sets us up for a landmark year in 2019."
Mr. Holler, who is President and CEO of Ponderosa Capital Inc., is an expert in biotechnology, investment banking and venture capital. He previously served as CEO and Partner of Lions Capital Corp., fund manager for BC Advantage Funds and the Lions Funds; as President and CEO of Xenon Pharmaceuticals Inc., a private genomics-based drug development company; as President and CEO of ID Biomedical Corporation, a vaccine development company sold to GlaxoSmithKline plc; and as a founding director of Angiotech Pharmaceuticals, a TSX/ NASDAQ listed medical device company. Before working in biotechnology and healthcare, Mr. Holler was an Investment Banker with Merrill Lynch Canada and Wood Gundy Inc. (now CIBC World Markets).
At the Board meeting Mr. Froese thanked departing Chairman Peter Wall for his service, saying: "On behalf of the Board, I would like to thank Peter for his contributions to Harvest One over the past few years and we're pleased he's staying on as a Director."
Harvest One is a global cannabis company that develops and provides innovative lifestyle and wellness products to consumers and patients in regulated markets around the world. The Company's range of lifestyle solutions is designed to enhance quality of life. Shareholders have significant exposure to the entire cannabis value chain through three wholly-owned subsidiaries; United Greeneries, a Licensed Producer; Satipharm (medical and nutraceutical); and Dream Water Global (consumer), and a minority interest in Burb Cannabis (retail operations). For more information, please visit www.harvestone.com.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. The forward-looking information contained in this press release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accept responsibility for the adequacy or accuracy of this release.